{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:27:46Z","timestamp":1794972466577,"version":"4.9.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Appropriate treatment of primary aldosteronism (PA) depends on accurate lateralization. <jats:sup>11<\/jats:sup>C-metomidate (MTO) is a tracer used in PET that provides functional information about the adrenal cortex. We aimed to perform MTO PET for patients with PA who are managed according to the guideline and to verify its correlation with other lateralization modalities and usefulness in outcome prediction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Seventeen patients with PA who underwent MTO PET and had \u22651 lateralization modality (adrenal venous sampling and\/or NP-59 adrenal scintigraphy) were included. SUV<jats:sub>max<\/jats:sub> of each adrenal gland (higher uptake side, HSUV<jats:sub>max<\/jats:sub>; lower uptake side, LSUV<jats:sub>max<\/jats:sub>) and the ratio of HSUV<jats:sub>max<\/jats:sub> to LSUV<jats:sub>max<\/jats:sub> (contrast) were compared with lateralization modalities, postsurgical outcomes, and medical treatment outcomes. Cutoff values were used as outcome predictors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>HSUV<jats:sub>max<\/jats:sub> and LSUV<jats:sub>max<\/jats:sub> increased in the order of bilateral, unilateral, and negative findings of CT, with opposite order of contrast. High discordant rate between MTO PET and other lateralization modalities was noted. Biochemical responders (n = 8) had significantly lower HSUV<jats:sub>max<\/jats:sub> and LSUV<jats:sub>max<\/jats:sub> than nonresponders, and clinical responders (n = 6) had borderline lower HSUV<jats:sub>max<\/jats:sub> than nonresponders. By optimal cutoff values of HSUV<jats:sub>max<\/jats:sub> and LSUV<jats:sub>max<\/jats:sub>, MTO PET was able to predict biochemical and clinical outcomes in patients with medical treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>According to adrenal CT findings, MTO PET presented different uptake patterns. Patients with PA under medical treatment showed significantly lower tracer uptake in responders. Thus, MTO PET may be a useful imaging biomarker to predict medical treatment outcome. Multicenter prospective study with a larger number of patients is needed for further validation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004369","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T18:26:04Z","timestamp":1665426364000},"page":"936-942","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Predicting Treatment Response in Primary Aldosteronism Using 11C-Metomidate Positron Emission Tomography"],"prefix":"10.1097","volume":"47","author":[{"given":"Ching-Chu","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Jung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Yung","family":"Peng","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff S.","family":"Chueh","sequence":"additional","affiliation":[{"name":"Department of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chen","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoh-Fang","family":"Yen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-44-1-1","article-title":"Primary aldosteronism, a new clinical entity","volume":"44","year":"1956","journal-title":"Ann Intern Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S2213-8587(16)30272-8","article-title":"Primary aldosteronism as a public health issue","volume":"4","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis","volume":"101","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/HJH.0b013e3283495cbb","article-title":"Primary aldosteronism: changes in cystatin C\u2013based kidney filtration, proteinuria, and renal duplex indices with treatment","volume":"29","year":"2011","journal-title":"J Hypertens"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1055\/s-0043-121706","article-title":"Health-related quality of life and mental health in primary aldosteronism: a systematic review","volume":"49","year":"2017","journal-title":"Horm Metab Res"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jfma.2018.01.006","article-title":"Targeted treatment of primary aldosteronism\u2014the consensus of Taiwan Society of Aldosteronism","volume":"118","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jfma.2020.08.001","article-title":"Taiwan mini-frontier of primary aldosteronism: updating detection and diagnosis","volume":"120","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S2213-8587(14)70069-5","article-title":"Adrenal vein sampling in primary aldosteronism: towards a standardised protocol","volume":"3","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2265.2009.03714.x","article-title":"Adrenal vein sampling for primary aldosteronism: time for a reality check","volume":"72","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-8587(16)30100-0","article-title":"Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial","volume":"4","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S2213-8587(16)30113-9","article-title":"Adrenal vein sampling for subtyping in primary aldosteronism","volume":"4","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-90-3-386","article-title":"Primary aldosteronism: diagnosis, localization, and treatment","volume":"90","year":"1979","journal-title":"Ann Intern Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1210\/jcem-71-4-825","article-title":"Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity","volume":"71","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2967\/jnumed.109.064873","article-title":"131I-6beta-iodomethyl-19-norcholesterol SPECT\/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00259-014-2692-z","article-title":"Prognostic value of semiquantification NP-59 SPECT\/CT in primary aldosteronism patients after adrenalectomy","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib17-20250621","first-page":"1224","article-title":"Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate","volume":"31","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1210\/jc.2005-2273","article-title":"[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings","volume":"91","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"bib19-20250621","first-page":"275","article-title":"PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate","volume":"41","year":"2000","journal-title":"J Nucl Med"},{"key":"bib20-20250621","first-page":"972","article-title":"Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG","volume":"45","year":"2004","journal-title":"J Nucl Med"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2011-1537","article-title":"Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)\u2013CT for lateralizing aldosterone secretion by Conn's adenomas","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/cen.13942","article-title":"(11)C-metomidate PET\/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice","volume":"90","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/EJE-20-0532","article-title":"Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism","volume":"183","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1007\/s00330-017-4930-9","article-title":"Comparison of C-arm computed tomography and on-site quick cortisol assay for adrenal venous sampling: a retrospective study of 178 patients","volume":"27","year":"2017","journal-title":"Eur Radiol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.113.02097","article-title":"An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism","volume":"63","year":"2014","journal-title":"Hypertension"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","year":"2018","journal-title":"JAMA Cardiol"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/HYPERTENSIONAHA.118.11382","article-title":"Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism","volume":"72","year":"2018","journal-title":"Hypertension"},{"key":"bib31-20250621","first-page":"982","article-title":"In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors","volume":"39","year":"1998","journal-title":"J Nucl Med"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejrad.2007.10.024","article-title":"Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas","volume":"69","year":"2009","journal-title":"Eur J Radiol"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00423-010-0681-7","article-title":"11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism","volume":"395","year":"2010","journal-title":"Langenbecks Arch Surg"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2342-9-6","article-title":"Masked volume wise principal component analysis of small adrenocortical tumours in dynamic [11C]-metomidate positron emission tomography","volume":"9","year":"2009","journal-title":"BMC Med Imaging"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"L11","DOI":"10.1530\/EJE-21-0048","article-title":"Response to letter on use of functional imaging by 11C-metomidate PET for primary aldosteronism subtyping","volume":"184","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"L9","DOI":"10.1530\/EJE-20-1402","article-title":"Functional imaging by 11C-metomidate PET: a really useless technique for primary aldosteronism subtyping?","volume":"184","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S2213-8587(16)30154-1","article-title":"Splitting atoms: the Endocrine Society guideline for the management of primary aldosteronism","volume":"4","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"644927","DOI":"10.3389\/fendo.2021.644927","article-title":"NP-59 adrenal scintigraphy as an imaging biomarker to predict KCNJ5 mutation in primary aldosteronism patients","volume":"12","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone\u2013producing adenomas and hereditary hypertension","volume":"331","year":"2011","journal-title":"Science"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00259-005-0062-6","article-title":"[18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers","volume":"33","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:03:33Z","timestamp":1750536213000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004369","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,12]]}}}